Source-grounded facts extracted from Arcadia Biosciences, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Arcadia Biosciences, Inc. entered into Purchase Agreement with an institutional accredited investor valued at approximately $4 million (effective 2026-06-11).
“On June 11, 2026, Arcadia Biosciences, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with an institutional accredited investor (the “Purchaser”) for the sale and issuance in a private placement”
Arcadia Biosciences, Inc. reported financial results for first quarter of 2026.
“On May 14, 2026 Arcadia Biosciences, Inc. (the “Company”) issued a press release announcing financial results for the first quarter of 2026.”
Arcadia Biosciences, Inc. engaged Ramirez Jimenez International CPAs as its auditor.
“the Audit Committee approved the engagement of Ramirez Jimenez International CPAs (“RJI”), effective immediately upon the dismissal of Deloitte, as the Company’s independent registered public accounting firm”
Arcadia Biosciences, Inc. dismissed Deloitte & Touche LLP as its auditor.
“dismissed Deloitte & Touche LLP (“Deloitte”) as the Company’s independent registered public accounting firm.”
Arcadia Biosciences, Inc. reported financial results for the fourth quarter and year ended December 31, 2025.
“On March 26, 2026 Arcadia Biosciences, Inc. (the “Company”) issued a press release announcing financial results for the fourth quarter and year ended December 31, 2025.”
Arcadia Biosciences, Inc. issued securities.
“On January 9, 2026, the Company agreed to reduce the exercise price for the Existing Options to $2.575 per share”
Arcadia Biosciences, Inc. issued 56,602 shares of warrant to H.C. Wainwright & Co., LLC for placement agent services.
“The Company also issued to Wainwright or its designees placement agent preferred investment options (the “Placement Agent Options”) to purchase that number of shares of Common Stock ("Placement Agent Option Shares") equal to 7.0% of the aggregate number of shares of Common Stock underlying the Existing Options exercised in the transaction, or 56,602 shares”
Arcadia Biosciences, Inc. issued to purchase up to 1,617,190 shares of Common Stock of warrant to certain investors (Participating Holders) for exercise of outstanding preferred investment options at reduced exercise price of $2.575 per share, aggregate gross proceeds of approximately $2.1 million.
“the Participating Holders agreed to exercise for cash the Existing Options at a reduced exercise price of $2.575 per share, in consideration for the Company's agreement to issue new unregistered preferred investment options (the “New Options”) to purchase up to 1,617,190 shares of Common Stock”
Arcadia Biosciences, Inc. entered into Inducement Letters with Participating Holders valued at Aggregate gross proceeds of approximately $2.1 million from exercise of Existing Options (effective 2026-01-09).
“On January 9, 2026, Arcadia Biosciences, Inc. (the “Company”) entered into inducement offer letter agreements (the “Inducement Letters”) with certain investors (the “Participating Holders”) pursuant to which such Participating Holders agreed to exercise certain outstanding preferred investment options to purchase an aggregate of 808,595 shares of the Company’s common stock ("Common Stock").”
Arcadia Biosciences, Inc. terminated Securities Exchange Agreement with Roosevelt Resources, LP (effective 2025-12-24).
“On December 24, 2025, the Company received a notice from Roosevelt indicating that it was terminating the Exchange Agreement with immediate effect pursuant to the Termination Provisions”
Thomas J. Schaefer was appointed as Class I Director at Arcadia Biosciences, Inc..
“On August 1, 2024, the board of directors (the “Board”) of Arcadia Biosciences, Inc. (“Arcadia” or the “Company”) appointed Thomas J. Schaefer, Arcadia’s current president and chief executive officer, to serve as a Class I director of the Company.”
Mark Kawakami was appointed as chief financial officer at Arcadia Biosciences, Inc..
“Arcadia’s board of directors appointed Mark Kawakami as Arcadia’s new chief financial officer to succeed Mr. Schaefer, effective as of July 5, 2024.”
Thomas J. Schaefer was appointed as president and chief executive officer at Arcadia Biosciences, Inc..
“Arcadia’s board of directors appointed Thomas J. Schaefer, Arcadia’s current chief financial officer, to the position of president and chief executive officer of Arcadia, effective as of July 5, 2024.”
Stanley Jacot, Jr. resigned as president, chief executive officer and director at Arcadia Biosciences, Inc..
“Mr. Jacot resigned as Arcadia’s president, chief executive officer and director.”
Arcadia Biosciences, Inc. completed a disposition involving Above Food Corp. and Above Food Ingredients Corp. for Parent and Buyer issued a promissory note in the original principal amount of $6,000,000 (closed 2024-05-14).
“Pursuant to the Purchase Agreement, Arcadia and Wellness sold to Buyer certain assets relating to Arcadia’s GoodWheat business (“Purchased Assets”) and Arcadia transferred to Buyer $2,000,000 of cash. The Purchase Agreement includes a number customary provisions addressing matters such as closing deliverables, representations and warranties, covenants, survival of the representations and warranties for a period of time after the closing, and indemnification obligations. The transactions contemplated by the Purchased Agreement closed on May 14, 2024. As consideration for the Purchased Assets and the $2,000,000 cash payment, Parent and Buyer issued a promissory note, dated May 14, 2024, in favor of Arcadia and in the original principal amount of $6,000,000 (“Promissory Note”).”
Arcadia Biosciences, Inc. completed a disposition involving Pioneer Hi-Bred International, Inc. for $4,000,000 in cash (closed 2024-05-13).
“worked to introgress the resistant starch durum wheat trait into elite germplasm lines. As consideration for the sale and license of Purchased Assets, Pioneer paid to Arcadia $4,000,000 in cash, which consideration was determined based on negotiations between the parties. The Agreement includes a number customary provisions addressing matters such as closing”
Arcadia Biosciences, Inc. entered into Asset Purchase Agreement with Pioneer Hi-Bred International, Inc. valued at $4,000,000 in cash (effective 2024-05-13).
“On May 13, 2024, Arcadia Biosciences, Inc. (“Arcadia”) entered into an Asset Purchase Agreement (the “Agreement”) with Pioneer Hi-Bred International, Inc. (“Pioneer”), an indirect, wholly-owned subsidiary of Corteva, Inc., pursuant to which on May 13, 2024 Arcadia sold or licensed to Pioneer certain patent and related rights associated with Arcadia’s resistant starch durum wheat trait (“Purchased Assets”).”
Arcadia Biosciences, Inc. reported financial results for the first quarter ended March 31, 2024.
“On May 9, 2024 Arcadia Biosciences, Inc. (the “Company”) issued a press release announcing financial results for the first quarter ended March 31, 2024.”
Arcadia Biosciences, Inc. reported financial results for the fourth quarter and year ended December 31, 2023.
“On March 28, 2024 Arcadia Biosciences, Inc. (the “Company”) issued a press release announcing financial results for the fourth quarter and year ended December 31, 2023.”
Laura Pitlik resigned as chief marketing officer at Arcadia Biosciences, Inc..
“On February 9, 2024, Laura Pitlik provided notice to Arcadia Biosciences, Inc. (“Arcadia”) of her resignation as Arcadia’s chief marketing officer, effective as of March 1, 2023 (the “Separation Date”).”
Arcadia Biosciences, Inc. reported the third quarter ended September 30, 2023 results: revenue 1,597, net income (2,567), EPS $1.89 per share.
“($ in thousands) Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 Favorable / (Unfavorable) 2023 2022 Favorable / (Unfavorable) $ % $ % Total revenues 1,597 1,570 27 2% 4,160 6,674 (2,514) (38%) Total operating expenses 4,839 5,561 722 13% 14,734 16,023 1,289 8% Loss from continuing operations (3,242) (3,991) 749 19% (10,574) (9,349)”
Arcadia Biosciences, Inc. reported the second quarter of 2023 results: revenue $1.3 million - $1.5 million.
“As of June 30, 2023, Arcadia Biosciences had approximately $18.8 million in cash and cash equivalents. The company anticipates second-quarter revenue in the range of $1.3 million - $1.5 million.”
Arcadia Biosciences, Inc. shareholders approved Advisory Vote on Executive Compensation at the 2023-06-06 meeting.
“PROPOSAL III: Advisory Vote on Executive Compensation The Company’s shareholders approved, on an advisory basis, the compensation paid to the Company’s named executive officers by the votes set forth in the table below: FOR AGAINST ABSTAIN BROKER NON-VOTES 149,708 25,098 57,107 201,624”
Arcadia Biosciences, Inc. shareholders approved Ratification of Selection of Independent Registered Public Accountants at the 2023-06-06 meeting.
“PROPOSAL II: Ratification of Selection of Independent Registered Public Accountants The appointment of Deloitte & Touche LLP as the Company’s independent registered public accountants for the year ending December 31, 2023, was ratified by the affirmative votes of the stockholders. There were no broker non-votes on this proposal. The results of the ratification were as follows: FOR AGAINST ABSTAIN 355,572 11,030 66,935”
Arcadia Biosciences, Inc. shareholders approved Election of Directors at the 2023-06-06 meeting.
“PROPOSAL I: Election of Directors The director nominees were elected to serve as a Class II directors until the Company’s annual meeting of stockholders in 2026, or until their successors are duly elected and qualified, or their earlier resignation, death, or removal. Due to plurality election, votes could only be cast in favor of or withheld from the nominees and thus votes against were not applicable. The results of the election were as follows: DIRECTOR NOMINEE FOR WITHHELD BROKER NON-VOTES Deborah Carosella 161,465 70,448 201,624 Gregory Waller 166,720 65,193 201,624”
Arcadia Biosciences, Inc. reported financial results for first quarter ended March 31, 2023.
“On May 11, 2023 Arcadia Biosciences, Inc. (the “Company”) issued a press release announcing financial results for the first quarter ended March 31, 2023.”
Arcadia Biosciences, Inc. reported financial results for fourth quarter and year ended December 31, 2022.
“On March 30, 2023 Arcadia Biosciences, Inc. (the “Company”) issued a press release announcing financial results for the fourth quarter and year ended December 31, 2022.”
Arcadia Biosciences, Inc. entered into Engagement Letter with H.C. Wainwright & Co., LLC (effective 2023-03-02).
“The Company entered into an engagement letter with H.C. Wainwright & Co., LLC (“Wainwright”) dated March 2, 2023 (the “Engagement Letter”), pursuant to which Wainwright agreed to serve as the Company’s exclusive placement agent for certain equity financing transactions, including the Private Placement.”
Arcadia Biosciences, Inc. amended Option Amendment Agreements with the Purchasers (effective 2023-03-02).
“Concurrent with the Private Placement, the Company entered into preferred investment option amendment agreements (the “Option Amendment Agreements”) with the Purchasers.”
Arcadia Biosciences, Inc. entered into Registration Rights Agreement with the Purchasers (effective 2023-03-02).
“Also on March 2, 2023 and in connection with the Private Placement, the Company entered into a registration rights agreement (the “Registration Rights Agreement”) with the Purchasers.”
Arcadia Biosciences, Inc. entered into Purchase Agreement with certain institutional and accredited investors (effective 2023-03-02).
“On March 2, 2023, Arcadia Biosciences, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional and accredited investors (the “Purchasers”)”
Arcadia Biosciences, Inc.: Approved and filed a Certificate of Amendment to effect a 1-for-40 reverse stock split of common stock (effective 2023-03-01).
“On February 27, 2023, Arcadia Biosciences, Inc. (the “Company”) filed a Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of Delaware to effect a 1-for-40 reverse stock split of the outstanding shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), effective as of 12:01 a.m. (Delaware time) on March 1, 2023 (the “Reverse Stock Split”).”
Arcadia Biosciences, Inc. shareholders approved To approve a proposal to adjourn the Special Meeting to a later date or dates, if necessary or appropriate, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of the Reverse Stock Split Proposal. at the 2023-02-15 meeting.
“2. To approve a proposal to adjourn the Special Meeting to a later date or dates, if necessary or appropriate, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of the Reverse Stock Split Proposal. FOR AGAINST ABSTAIN Broker Non-Votes 9,995,797,812 1,260,616,357 381,278,898 --”
Arcadia Biosciences, Inc. shareholders approved To approve an amendment to the Company’s amended and restated certificate of incorporation to effect, at the discretion of the Company’s Board of Directors (“Board”) but prior to June 30, 2023, a reverse stock split of all of the outstanding shares of our Common Stock at a ratio in the range of 1-fo at the 2023-02-15 meeting.
“1. To approve an amendment to the Company’s amended and restated certificate of incorporation to effect, at the discretion of the Company’s Board of Directors (“Board”) but prior to June 30, 2023, a reverse stock split of all of the outstanding shares of our Common Stock at a ratio in the range of 1-for-10 to 1-for-40, with such ratio to be determined by the Board in its discretion (“Reverse Stock Split Proposal”). FOR AGAINST ABSTAIN Broker Non-Votes 9,730,160,440 1,678,239,563 229,293,064 --”
Thomas J. Schaefer was appointed as chief financial officer at Arcadia Biosciences, Inc..
“On November 30, 2022 and effective January 3, 2022, Arcadia’s board of directors appointed Thomas J. Schaefer as Arcadia’s new chief financial officer to succeed Ms. Haley.”
Pamela Haley resigned as chief financial officer at Arcadia Biosciences, Inc..
“On November 28, 2022, Pamela Haley provided notice to Arcadia Biosciences, Inc. (“Arcadia”) of her resignation as Arcadia’s chief financial officer, effective as of January 3, 2022.”
Arcadia Biosciences, Inc. reported the third quarter ended September 30, 2022 results: revenue $1.9 million, net income $2.9 million, EPS $0.12 per share.
“are included in the Form 8-K filed today, available in the Investors section of the company’s website under SEC Filings . 1 Revenues In the third quarter of 2022, revenues were $1.9 million, compared to $2.4 million in the third quarter of 2021 – a $498,000 decrease driven primarily by lower body care and GLA revenue, partially offset by GoodWheat pasta sales.”
Stanley E. Jacot, Jr. was appointed as Class III Director at Arcadia Biosciences, Inc..
“On June 2, 2022, Arcadia’s board of directors appointed Stanley E. Jacot, Jr., Arcadia’s current president and chief executive officer, to serve as a Class III director of the Company.”
Kevin Comcowich resigned as Interim President and Chief Executive Officer at Arcadia Biosciences, Inc..
“In connection with Mr. Jacot’s appointment, Kevin Comcowich resigned as interim president and chief executive officer of the Company, effective February 2, 2022.”
Stanley Jacot, Jr. was appointed as President and Chief Executive Officer at Arcadia Biosciences, Inc..
“On February 2, 2022, (the “Effective Date”), Arcadia Biosciences, Inc. (“the Company”) hired Stanley Jacot, Jr. as the new president and chief executive officer of the Company.”
Kevin Comcowich was appointed as Interim Chief Executive Officer at Arcadia Biosciences, Inc..
“The Company has appointed Kevin Comcowich, the current chairman of the Arcadia Board of Directors, as the Company’s Interim Chief Executive Officer, effective January 1, 2022, as the board of directors finalizes its search for a permanent CEO.”
Matt Plavan resigned as Chief Executive Officer, President at Arcadia Biosciences, Inc..
“On December 14, 2021, Matt Plavan submitted his resignation from his positions as Chief Executive Officer, President and as a member of the Board of Directors (the “Board”) of Arcadia Biosciences, Inc. (the “Company” or "Arcadia"), effective December 31, 2021 (“Separation Date”).”
Chris Cuvelier departed as Chief Growth Officer at Arcadia Biosciences, Inc..
“On November 15, 2021, Arcadia Biosciences, Inc. (the “Company”) and Chris Cuvelier determined that Mr. Cuvelier's employment as the Company’s Chief Growth Officer will end effective as of November 30, 2021.”
Matthew Plavan departed as Chief Executive Officer at Arcadia Biosciences, Inc..
“the Company and Matthew Plavan, the Company’s current Chief Executive Officer, entered into a Transition Agreement on September 3, 2021”
Laura Pitlik was appointed as Chief Marketing Officer at Arcadia Biosciences, Inc..
“On July 12, 2021, Arcadia Biosciences, Inc. (the “Company”) hired Laura Pitlik as Arcadia’s new Chief Marketing Officer, in which capacity she will oversee marketing activities for the company as well as its consumer nutrition, health and wellness brands, including GoodWheat, Soul Spring, Saavy Naturals, Zola coconut water and SONOVA GLA safflower oil.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.